Vitamin C and antibiotics—a new one-two punch for knocking-out cancer stem cells.

June 12, 2017
Model of a vitamin C molecule. Black is carbon, red is oxygen, and white is hydrogen. Credit: Public Domain

Cancer stem cells, which fuel the growth of fatal tumours, can be knocked out by a one-two combination of antibiotics and Vitamin C in a new experimental strategy, published by researchers at the University of Salford, UK.

The antibiotic, doxycycline, followed by doses of ascorbic acid (Vitamin C), were surprisingly effective in killing the under laboratory conditions, according to the research published in the journal Oncotarget.

In boxing terms, this would be the equivalent of two blows delivered in rapid succession; a left-hand jab, followed by a right cross.

The researchers say their method offers a new explanation for how to prevent cells from becoming treatment-resistant and how combinations therapies can be developed to overcome drug resistance.

Professor Michael Lisanti, who designed the study, explained: "We now know that a proportion of cancer cells escape chemotherapy and develop ; we established this new strategy to find out how they do it.

"We suspected the answer lay in the fact that certain cancer cells – which we call metabolically flexible—are able to switch their fuel source. Thus, when the drug treatment reduces the availability of a particular nutrient, the flexible cancer cells can feed themselves with an ."

This new combination approach prevents cancer cells from changing their diet (metabolically inflexible), and effectively starves them, by preventing them from using any other available types of bio-fuels.

The team at the University of Salford's Biomedical Research Centre, added doxycycline in ever increasing doses over a three-month period, to induce metabolic inflexibility. The result was to leave the cancer cells alive, but severely attenuated and depleted, so that they would be much more susceptible to starvation, by a second metabolic "punch".

First, the researchers inhibited the tumour cell mitochondria, by restricting the cancer only to glucose as a ; then, they took away their glucose, effectively starving the to death.

"In this scenario, Vitamin C behaves as an inhibitor of glycolysis, which fuels energy production in mitochondria, the "powerhouse" of the cell, explained co-author Dr Federica Sotgia.

The Salford team recently showed Vitamin C to be up to ten times more effective at stopping than pharmaceuticals such as 2-DG, but they say that when Vitamin C is combined with an antibiotic, it is up to ten times more effective, making it nearly 100 times more effective than 2-DG.

As doxycycline and Vitamin C are both relatively non-toxic, this could dramatically reduce the possible side-effects of anti-cancer therapy.

The Salford team also identified eight other drugs that could be used as a "second-punch" after the antibiotic regime, including berberine (a natural product) – and a number of cheap non-toxic FDA approved drugs.

Professor Lisanti added: "This is further evidence that Vitamin C and other non-toxic compounds may have a role to play in the fight against cancer.

"Our results indicate it is a promising agent for clinical trials, and a as an add-on to more conventional therapies, to prevent tumour recurrence, further disease progression and metastasis."

Explore further: Vitamin C effective in targeting cancer stem cells

More information: Vitamin C and Doxycycline: A synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). DOI: 10.18632/oncotarget.18428

Related Stories

Vitamin C effective in targeting cancer stem cells

March 8, 2017
Vitamin C is up to 10 times more effective at stopping cancer cell growth than pharmaceuticals such as 2-DG, according to scientists in Salford, UK.

Stem cell 'marking' study offers alterative hypothesis of cancer metastasis

January 18, 2017
Stem cells are among the most energetically activated, migratory and proliferative sub-populations of tumour cells, according to observations by scholars at the Biomedical Research Centre at the University of Salford.

New gene discovered driving drug resistance

April 4, 2017
Scientists in Salford, U.K., have identified a gene which is 'revving the engine of cancer' against the world's most common breast cancer drug.

Schoolgirl comment points to antibiotics as new cancer treatments

January 28, 2015
Professor Michael P. Lisanti, Director of the Breakthrough Breast Cancer Unit, led the research. He was inspired to look at the effects of antibiotics on the mitochondria of cancer stem cells by a conversation with his daughter ...

Vitamin A may help improve pancreatic cancer chemotherapy

May 24, 2016
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL). The promising initial results ...

Treating cancer with drugs for diabetes and hypertension

December 27, 2016
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers led by Prof. Michael Hall at the Biozentrum of the University of Basel has also reported that ...

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.